Corcept Therapeutics Inc

-1.18 (-5.55%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.19B
Current PE22.48
Forward PE 22.82
2yr Forward PE 19.12
See more stats
Estimates Current Quarter
Revenue$97.65 Million
Adjusted EPS$0.22
See more estimates
10-Day MA$20.51
50-Day MA$20.70
200-Day MA$23.10
See more pivots

Corcept Therapeutics Inc Stock, NASDAQ:CORT

149 Commonwealth Drive, Menlo Park, California 94025
United States of America
Phone: +1.650.327.3270
Number of Employees: 236


Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.